Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to $137.2 million.

  • Avidity Biosciences' Accumulated Expenses rose 65194.89% to $137.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.2 million, marking a year-over-year increase of 65194.89%. This contributed to the annual value of $64.7 million for FY2024, which is 35152.42% up from last year.
  • Per Avidity Biosciences' latest filing, its Accumulated Expenses stood at $137.2 million for Q3 2025, which was up 65194.89% from $95.2 million recorded in Q2 2025.
  • Avidity Biosciences' Accumulated Expenses' 5-year high stood at $137.2 million during Q3 2025, with a 5-year trough of $2.7 million in Q1 2021.
  • Moreover, its 5-year median value for Accumulated Expenses was $8.9 million (2021), whereas its average is $22.9 million.
  • In the last 5 years, Avidity Biosciences' Accumulated Expenses skyrocketed by 2516.78% in 2022 and then skyrocketed by 65194.89% in 2025.
  • Quarter analysis of 5 years shows Avidity Biosciences' Accumulated Expenses stood at $8.9 million in 2021, then grew by 25.17% to $11.2 million in 2022, then grew by 28.11% to $14.3 million in 2023, then surged by 351.52% to $64.7 million in 2024, then surged by 111.91% to $137.2 million in 2025.
  • Its Accumulated Expenses stands at $137.2 million for Q3 2025, versus $95.2 million for Q2 2025 and $12.8 million for Q1 2025.